Skip to main content
SpringerLink
Log in

Validierung von Interaktionsdatenbanken in der Psychopharmakotherapie

Validation of interaction databases in psychopharmacotherapy

  • Originalien
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Interaktionsdatenbanken sind durch zunehmende Polypharmazie ein immer wichtigeres Tool zur Erhöhung der Arzneimitteltherapiesicherheit. Es stehen mehrere Interaktionsdatenbanken zur Verfügung. Unklar ist jedoch, welche die besten Ergebnisse liefert und somit die höchste Sicherheit für den Benutzer und die Patienten. Eine entsprechende Validierung deutschsprachiger Datenbanken gibt es bislang nicht.

Ziel

Validierung deutschsprachiger Interaktionsdatenbanken bezüglich Trefferquote, Handlungsanweisung, Literaturangabe, Mechanismus der Wechselwirkung und Schweregrad.

Methode

Es wurden dazu 36 Interaktionspaare, die drei bis fünf Jahre vor der Validierung publiziert wurden, in fünf unterschiedlichen deutschsprachigen Datenbanken getestet. Neben der Trefferquote wurden auch Handlungsanweisungen, Literatur, Mechanismus und Schweregradeinstufung bewertet.

Ergebnisse

Alle Datenbanken zeigten Schwächen bei der Trefferquote, die maximal bei 66,67 % lag. Hinsichtlich der Gesamtpunktzahl schnitt MediQ mit 104 von 180 möglichen Punkten am besten ab. PsiacOnline erzielte 83 Punkte, arznei-telegramm® 58, ifap index® 54 und die ABDA-Datenbank 49 Punkte. Die am besten geeignete Datenbank für den Bereich der Psychopharmakotherapie scheint aufgrund dieser Validierung MediQ zu sein.

Diskussion

Auch bei dieser Datenbank sind jedoch noch Verbesserungen, insbesondere die Trefferquote betreffend, nötig, um dem Anwender mehr Sicherheit zu geben.

Abstract

Background

Drug-drug interaction databases are an important tool to increase drug safety in polypharmacy. There are several drug interaction databases available but it is unclear which one shows the best results and therefore increases safety for the user of the databases and the patients. So far, there has been no validation of German drug interaction databases.

Goal

Validation of German drug interaction databases regarding the number of hits, mechanisms of drug interaction, references, clinical advice, and severity of the interaction.

Methods

A total of 36 drug interactions which were published in the last 3–5 years were checked in 5 different databases. Besides the number of hits, it was also documented if the mechanism was correct, clinical advice was given, primary literature was cited, and the severity level of the drug-drug interaction was given.

Results

All databases showed weaknesses regarding the hit rate of the tested drug interactions, with a maximum of 67.7% hits. The highest score in this validation was achieved by MediQ with 104 out of 180 points. PsiacOnline achieved 83 points, arznei-telegramm® 58, ifap index® 54 and the ABDA-database 49 points. Based on this validation MediQ seems to be the most suitable databank for the field of psychopharmacotherapy.

Discussion

The best results in this comparison were achieved by MediQ but this database also needs improvement with respect to the hit rate so that the users can rely on the results and therefore increase drug therapy safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Sandson N (2005) Drug-drug interactions: the silent epidemic. Psychiatr Serv 56:22–24

    Article  PubMed  Google Scholar 

  2. Schnurrer JU, Frolich JC (2003) Incidence and prevention of lethal undesirable drug effects. Internist (Berl) 44:889–895

    Article  CAS  Google Scholar 

  3. Comer JS, Olfson M, Mojtabai R (2010) National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. J Am Acad Child Adolesc Psychiatry 49(10):1001–1010. doi:10.1016/j.jaac.2010.07.007

    Article  PubMed  PubMed Central  Google Scholar 

  4. Frye MA, Ketter TA, Leverich GS et al (2000) The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61:9–15

    Article  CAS  PubMed  Google Scholar 

  5. Gyllenberg D, Sourander A (2012) Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 nationwide birth cohort study. Nord J Psychiatry 66(5):336–342. doi:10.3109/08039488.2011.644809

    Article  PubMed  Google Scholar 

  6. Abarca J, Colon LR, Wang VS et al (2006) Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm 12:383–389

    PubMed  Google Scholar 

  7. Barrons R (2004) Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 61:380–385

    PubMed  Google Scholar 

  8. Gandhi TK, Weingart SN, Borus J et al (2003) Adverse drug events in ambulatory care. N Engl J Med 348:1556–1564. doi:10.1056/nejmsa020703

    Article  PubMed  Google Scholar 

  9. Goldberg RM, Mabee J, Chan L et al (1996) Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14:447–450. doi:10.1016/S0735-6757(96)90147-3

    Article  CAS  PubMed  Google Scholar 

  10. Isaac T, Weissman JS, Davis RB et al (2009) Overrides of medication alerts in ambulatory care. Arch Intern Med 169:305–311. doi:10.1001/archinternmed.2008.551

    Article  PubMed  Google Scholar 

  11. Lin CP, Payne TH, Nichol WP et al (2008) Evaluating clinical decision support systems: monitoring CPOE order check override rates in the Department of Veterans Affairs’ Computerized Patient Record System. J Am Med Inform Assoc 15(5):620–626. doi:10.1197/jamia.M2453

    Article  PubMed  PubMed Central  Google Scholar 

  12. Mille F, Schwartz C, Brion F et al (2008) Analysis of overridden alerts in a drug-drug interaction detection system. Int J Qual Health Care 20:400–405. doi:10.1093/intqhc/mzn038

    Article  PubMed  Google Scholar 

  13. Payne TH, Nichol WP, Hoey P et al (2002) Characteristics and override rates of order checks in a practitioner order entry system. AMIA Annual Symposium AMIA Symposium. Proceedings., S 602–606

    Google Scholar 

  14. Weingart SN, Toth M, Sands DZ et al (2003) Physicians’ decisions to override computerized drug alerts in primary care. Arch Intern Med 163:2625–2631. doi:10.1001/archinte.163.21.2625

    Article  PubMed  Google Scholar 

  15. Malone DC, Abarca J, Skrepnek GH et al (2007) Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. Med Care 45:456–462. doi:10.1097/01.mlr.0000257839.83765.07

    Article  PubMed  Google Scholar 

  16. Vonbach P, Dubied A, Krahenbuhl S et al (2008) Evaluation of frequently used drug interaction screening programs. Pharm World Sci 30:367–374. doi:10.1007/s11096-008-9191-x

    Article  PubMed  Google Scholar 

  17. Spyridi S, Sokolaki S, Nimatoudis J et al (2009) Status epilepticus in a patient treated with olanzapine and mirtazapine. Int J Clin Pharmacol Ther 47:120–123

    Article  CAS  PubMed  Google Scholar 

  18. Hawkins DJ, Unwin P (2008) Paradoxical and severe hypotension in response to adrenaline infusions in massive quetiapine overdose. Crit Care 10:320–322

    Google Scholar 

  19. Pollack TM, McCoy C, Stead W (2009) Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy 29:1386–1391. doi:10.1592/phco.29.11.1386

    Article  CAS  PubMed  Google Scholar 

  20. Rahman A, Mican LM, Fischer C et al (2009) Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother 43:822–830. doi:10.1345/aph.1L617

    Article  CAS  PubMed  Google Scholar 

  21. Angelini MC, MacCormack-Gagnon J, Dizio S (2009) Increase in plasma levels of clozapine after addition of isoniazid. J Clin Psychopharmacol 29:190–191. doi:10.1097/jcp.0b013e31819a6b53

    Article  PubMed  Google Scholar 

  22. Nakamura A, Mihara K, Nagai G et al (2009) Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit 31:575–578. doi:10.1097/ftd.0b013e3181b6326a

    Article  CAS  PubMed  Google Scholar 

  23. Schwartz AR, Pizon AF, Brooks DE (2008) Dextromethorphan-induced serotonin syndrome. Clin Toxicol (Phila) 46:771–773

    Article  CAS  Google Scholar 

  24. Church CO, Callen EC (2009) Myxedema coma associated with combination aripiprazole and sertraline therapy. Ann Pharmacother 43:2113–2116. doi:10.1345/aph.1m369

    Article  PubMed  Google Scholar 

  25. Billups SJ, Delate T, Dugan D (2009) Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol Drug Saf 18:253–257. doi:10.1002/pds.1697

    Article  CAS  PubMed  Google Scholar 

  26. Stanford SC, Stanford BJ, Gillman PK (2010) Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J Psychopharmacol (Oxford) 24(10):1433–1438. doi:10.1177/0269881109105450

    Article  CAS  Google Scholar 

  27. Tsao YY, Gugger JJ (2009) Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine. Ann Pharmacother 43:1366–1369. doi:10.1345/aph.1m067

    Article  PubMed  Google Scholar 

  28. Forget P, le Polain de Waroux B, Wallemacq P et al (2008) Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study. J Pain Symptom Manage 36:92–96. doi:10.1016/j.jpainsymman.2007.09.006

    Article  CAS  PubMed  Google Scholar 

  29. Nikolic M, Noorani A, Park G (2009) Interaction between clonidine and escitalopram. Br J Anaesth 102:567–568. doi:10.1093/bja/aep034

    Article  CAS  PubMed  Google Scholar 

  30. Garcia A (2008) Adverse effects of propafenone after long-term therapy with the addition of citalopram. Am J Geriatr Pharmacother 6:96–99. doi:10.1016/j.amjopharm.2008.05.001

    Article  CAS  PubMed  Google Scholar 

  31. Gareri P, De Fazio P, Gallelli L et al (2008) Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. Ann Pharmacother 42:434–438. doi:10.1345/aph.1k405

    Article  CAS  PubMed  Google Scholar 

  32. Koga M, Kodaka F, Miyata H et al (2009) Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine. Acta Psychiatr Scand 120:329–331. doi:10.1111/j.1600-0447.2009.01433.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Monastero R, Camarda R, Camarda C (2007) Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer’s disease. Clin Ther 29:2706–2709. doi:10.1016/j.clinthera.2007.12.026

    Article  CAS  PubMed  Google Scholar 

  34. Moellentin D, Picone C, Leadbetter E (2008) Memantine-induced myoclonus and delirium exacerbated by trimethoprim. Ann Pharmacother 42:443–447. doi:10.1345/aph.1K619

    Article  CAS  PubMed  Google Scholar 

  35. Tahiroglu AY, Avci A (2007) Polypharmacy and EPS in a child; a case report. Psychopharmacol Bull 40:129–133

    PubMed  Google Scholar 

  36. Schlienger R, Kurmann M, Drewe J et al (2000) Inhibition of phenprocoumon anticoagulation by carbamazepine. Eur Neuropsychopharmacol 10:219–221

    Article  CAS  PubMed  Google Scholar 

  37. Vevelstad M, Pettersen S, Tallaksen C et al (2009) O‑demethylation of codeine to morphine inhibited by low-dose levomepromazine. Eur J Clin Pharmacol 65:795–801. doi:10.1007/s00228-009-0640-9

    Article  CAS  PubMed  Google Scholar 

  38. Chen YC, Shen YC, Hung YJ et al (2007) Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 103:257–261. doi:10.1016/j.jad.2007.01.023

    Article  CAS  PubMed  Google Scholar 

  39. Annapandian VM, John GT, Mathew BS et al (2009) Pharmacokinetic interaction between sodium valproate and mycophenolate in renal allograft recipients. Transplantation 88:1143–1145. doi:10.1097/tp.0b013e3181bb99ff

    Article  CAS  PubMed  Google Scholar 

  40. Striano P, Zara F, Minetti C et al (2009) Chitosan may decrease serum valproate and increase the risk of seizure reappearance. BMJ 339:b3751. doi:10.1136/bmj.b3751

    Article  PubMed  Google Scholar 

  41. de Leon J, Kiesel JL, Fleming MW et al (2009) Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: a case report. J Clin Psychopharmacol 29:509–511. doi:10.1097/jcp.0b013e3181b4b07c

    Article  PubMed  Google Scholar 

  42. Xiong GL, Ferranti J, Leamon MH (2008) Toxic interaction between valproate and oxcarbazepine: a case detected by the free valproate level. J Clin Psychopharmacol 28:472–473. doi:10.1097/jcp.0b013e31817ea9e6

    Article  PubMed  Google Scholar 

  43. Walder A, Baumann P (2009) Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions? Acta Medica (Hradec Kralove) 52:15–18

    Article  CAS  Google Scholar 

  44. Bracamonte JD, Underhill M, Sarmiento P (2010) Acute pancreatitis associated with lisinopril and olanzapine. Am J Health Syst Pharm 67:214–216. doi:10.2146/ajhp080519

    Article  PubMed  Google Scholar 

  45. Wu ML, Deng JF (2009) Serotonin toxicity caused by moclobemide too soon after paroxetine-selegiline. J Chin Med Assoc 72:446–449. doi:10.1016/s1726-4901(09)70404-6

    Article  CAS  PubMed  Google Scholar 

  46. Nichols AI, Fatato P, Shenouda M et al (2009) The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 49:219–228. doi:10.1177/0091270008326716

    Article  CAS  PubMed  Google Scholar 

  47. Fraile P, Garcia-Cosmes P, Garcia T et al (2009) Hypotension, as consequence of the interaction between tacrolimus and mirtazapine, in a patient with renal transplant. Nephrol Dial Transplant 24:1999–2001. doi:10.1093/ndt/gfp127

    Article  PubMed  Google Scholar 

  48. Kelesidis T, Kelesidis I (2009) Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin. Clin Ther 31:2894–2899. doi:10.1016/j.clinthera.2009.12.008

    Article  PubMed  Google Scholar 

  49. Lee J, Franz L, Goforth HW (2009) Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. Psychosomatics 50:638–639. doi:10.1176/appi.psy.50.6.638

    Article  PubMed  Google Scholar 

  50. Kharasch ED, Mitchell D, Coles R et al (2008) Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 52:1663–1669. doi:10.1128/aac.01600-07

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Totah RA, Sheffels P, Roberts T et al (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363–374. doi:10.1097/aln.0b013e3181642938

    Article  CAS  PubMed  Google Scholar 

  52. Laekeman G, Zwaenepoel L, Reyntens J et al (2008) Osteoporosis after combined use of a neuroleptic and antidepressants. Pharm World Sci 30:613–616. doi:10.1007/s11096-008-9231-6

    Article  PubMed  Google Scholar 

  53. Hahn M, Roll SC (2012) Increasing drug therapy safety in psychiatry: implementing a pharmacist on the ward. Pharmacopsychiatry. doi:10.1055/s-0032-1326750 (45-A7)

    Google Scholar 

  54. Hahn M, Roll SC (2012) A new approach to pharmaceutical care: experiences with the “Eichberger” Model in a psychiatric clinic in Germany. Drugs Ther Perspect 28(9):24–26. doi:10.1007/bf03262124

    Google Scholar 

  55. Hahn M et al (2013) Drug-drug interactions in psychiatry. Psychiatr Prax 40(3):154–158

    Article  PubMed  Google Scholar 

Download references

Danksagung

Frau Christiane Kuffner für ihre Mithilfe.

Author information

Authors and Affiliations

  1. Vitos Klinik Eichberg, Kloster-Eberbach-Str.4, 65346, Eltville, Deutschland

    M. Hahn & S. C. Roll

Authors
  1. M. Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. C. Roll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Hahn.

Ethics declarations

Interessenkonflikt

M. Hahn und S.C. Roll geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hahn, M., Roll, S.C. Validierung von Interaktionsdatenbanken in der Psychopharmakotherapie. Nervenarzt 89, 319–326 (2018). https://doi.org/10.1007/s00115-017-0385-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-017-0385-0

Schlüsselwörter

Keywords

Search

Navigation